TScan Therapeutics Announces First Patient Infused With TSC-101 In Pivotal Phase 3 ALLOHA-2 Trial For AML, MDS Relapse Prevention After Transplant
Share
Why It Matters
TScan Therapeutics just gave medicine to the first patient in an important test of a new treatment to help people after blood cancer transplants. This is a big step forward for the company, so watch whether they report good results from this test over time.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.